RTP Mobile Logo

GICancers15/Audio

OVERVIEW OF ACTIVITY

COCP15/3

OVERVIEW OF ACTIVITY
In 2015 in the United States alone it is estimated that 220,800 new cases of prostate cancer (PC) will occur. With an estimated 27,540 deaths in 2015, PC is the second-leading cause of cancer death in men. The disease has a tremendous global impact and has become the center of extensive ongoing clinical research. For this reason, the clinical management of PC is frequently in a state of evolution, necessitating rapid and consistent clinician access to emerging data sets relevant to the continuous delivery of quality cross-functional care.

GUCancers15/Immunotherapy

TARGET AUDIENCE
This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals.

OVERVIEW OF ACTIVITY

GUCancers15/Prostate

TARGET AUDIENCE
This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals.

OVERVIEW OF ACTIVITY

Oncology Nursing Update Hodgkin and Non-Hodgkin Lymphoma Edition

OVERVIEW OF ACTIVITY

WLCC2015

TARGET AUDIENCE
This educational activity has been designed to meet the educational needs of medical oncologists, hematology-oncology fellows, nurse practitioners and other allied cancer professionals involved in the treatment of lung cancer.

OVERVIEW OF ACTIVITY

PCUTT115

OVERVIEW OF ACTIVITY

Oncology Nursing Update Lung Cancer Edition, Issue 1, 2015

OVERVIEW OF ACTIVITY
Lung cancer is one of the most rapidly evolving fields in oncology nursing and is a major public health concern. In
2015, lung cancer will culminate in 221,200 new cases and an estimated 158,040 deaths in the United States.
Progress in the screening, prevention and treatment of this disease has been limited, and approximately 85% of
patients who develop lung cancer will die of it. Traditional chemotherapy, surgery and radiation therapy have had a
modest effect on long-term outcomes. However, the advent of novel therapies has led to recent improvements in
disease-free and overall survival in select patient populations. Additionally, published results from ongoing clinical

CaCU115

OVERVIEW OF ACTIVITY

ASCOGI15

TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows, gastrointestinal surgeons and other healthcare providers involved in the treatment of gastrointestinal (GI) cancers.

SABCS15

TARGET AUDIENCE
This activity is intended for medical oncologists and other healthcare providers involved in the treatment of breast cancer.

OVERVIEW OF ACTIVITY
Breast cancer remains the most frequently diagnosed cancer in women, and in 2014 in the United States alone the disease culminated in an estimated 232,670 new cases and 40,000 deaths. Advances in screening and prevention have resulted in a steady down-stage migration at the time of disease presentation, such that only 5% of women have identifiable distant metastases at primary diagnosis. Consequently, the number of individuals living with breast cancer has increased substantially, as has the population “at risk” for recurrent disease.

5MJCASH2015/2

OVERVIEW OF ACTIVITY
Each year, thousands of clinicians, basic scientists and other industry professionals sojourn to major international oncology conferences, like the American Society of Hematology (ASH) annual meeting, to hone their skills, network with colleagues and learn about recent advances altering state-of-the-art management in hematologic oncology. As such, these events have become global stages where exciting science, cutting-edge concepts and practice-changing data emerge on a truly grand scale. This massive outpouring of information has enormous benefits for the hematologic oncology community, but the truth is it also creates a major challenge for practicing oncologists and hematologists.

COCP15/2

OVERVIEW OF ACTIVITY
In 2015 in the United States alone it is estimated that 220,800 new cases of prostate cancer (PCa) will occur. With an estimated 27,540 deaths in 2015, PCa is the second-leading cause of cancer death in men. The disease has a tremendous global impact and has become the center of extensive ongoing clinical research. For this reason, the clinical management of PCa is frequently in a state of evolution, necessitating rapid and consistent clinician access to emerging data sets relevant to the continuous delivery of quality cross-functional care.

ASHMM15

TARGET AUDIENCE
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of hematologic cancers.

OVERVIEW OF ACTIVITY

5MJCASH2015

OVERVIEW OF ACTIVITY

Each year, thousands of clinicians, basic scientists and other industry professionals sojourn to major international oncology conferences, like the American Society of Hematology (ASH) annual meeting, to hone their skills, network with colleagues and learn about recent advances altering state-of-the-art management in hematologic oncology. As such, these events have become global stages where exciting science, cutting-edge concepts and practice-changing data emerge on a truly grand scale. This massive outpouring of information has enormous benefits for the hematologic oncology community, but the truth is it also creates a major challenge for practicing oncologists and hematologists.